Positioned to Accelerate

Investor Presentation
August 2, 2017
 Cautionary Note Regarding Forward-Looking Statements
This presentation includes forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking
statements generally can be identified by the use of words such as anticipate, expect, intend, could, may, will, believe,
estimate, look forward, forecast, goal, target, project, continue, outlook, guidance, future, other words of similar meaning
and the use of future dates. Forward-looking statements in this presentation include, but are not limited to, statements about the
companys anticipated financial results for 2017, including net sales from continuing operations, adjusted EBITDA from continuing
operations and adjusted earnings per share from continuing operations; anticipated sales acceleration in the second half of the year and
benefits from expanded U.S. sales force and new product launches, anticipated sales and cost synergies and dis-synergies and the timing
thereof; and the companys ability to achieve its key financial goals. Forward-looking statements by their nature address matters that are,
to different degrees, uncertain. Each forward-looking statement contained in this presentation is subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties
include, among others, the failure to integrate the legacy Wright and Tornier businesses and realize net sales synergies and cost savings
from the merger with Tornier or delay in realization thereof; operating costs and business disruption as a result of the merger, including
adverse effects on employee retention and sales force productivity and on business relationships with third parties; integration costs;
actual or contingent liabilities; adverse effects of diverting resources and attention to providing transition services to the purchaser of the
large joints business; the adequacy of the companys capital resources and need for additional financing; the timing of regulatory
approvals and introduction of new products; physician acceptance, endorsement, and use of new products; failure to achieve the
anticipated benefits from approval of AUGMENT Bone Graft; the effect of regulatory actions, changes in and adoption of reimbursement
rates; product liability claims and product recalls; pending and threatened litigation; risks associated with the metal-on-metal master
settlement agreement and the settlement agreement with the three settling insurers; risks associated with international operations and
expansion; fluctuations in foreign currency exchange rates; other business effects, including the effects of industry, economic or political
conditions outside of the companys control; reliance on independent distributors and sales agencies; competitor activities; changes in tax
and other legislation; and the risks identified under the heading Risk Factors in Wrights Annual Report on Form 10-K for the year ended
December 25, 2016 filed by Wright with the SEC on February 23, 2017 and in other subsequent SEC filings by Wright. Investors should
not place considerable reliance on the forward-looking statements contained in this presentation. Investors are encouraged to read
Wrights filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking
statements in this presentation speak only as of the date of this presentation, and Wright undertakes no obligation to update or revise any
of these statements. Wrights business is subject to substantial risks and uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration to these risks and uncertainties.

2
 Note on Non-GAAP Financial Measures
Wright uses non-GAAP financial measures, including constant currency net sales, gross margin from
continuing operations, as adjusted, and EBITDA from continuing operations, as adjusted. Wrights
management team believes that the presentation of these measures provides useful information to investors
and that these measures may assist investors in evaluating the companys operations, period over period.
EBITDA is calculated by adding back to net income charges for interest, income taxes and depreciation and
amortization expenses. While it is not possible to reconcile the adjusted EBITDA forecast in this
presentation to the nearest metric under U.S. generally accepted accounting principles (GAAP) of the
combined business without unreasonable effort, the adjusted EBITDA forecast excludes non-cash stock
based compensation expense and non-operating income and expense, as well as the expected impact of
transaction and transition costs, all of which may be highly variable, difficult to predict and of a size that
could have substantial impact on the companys reported results of operations for a period. Investors should
consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to,
measures of financial performance prepared in accordance with GAAP. Reconciliations of the non-GAAP
financial measures used in this presentation to most comparable GAAP measures can be found on our
website.

3
Leader in 3 of the Fastest-Growing
Orthopaedic Markets
UPPER EXTREMITIES | LOWER EXTREMITIES | BIOLOGICS

~$8B #1
Global extremities/ Wright Medical position
biologics market in extremities market

~2X
Wright growth rate vs.
the market

4
Differentiators
That Matter

Recognized Strong
leader in Global footprint Strong R&D emphasis
high-growth with the largest Leading pipeline on medical
extremities specialized technologies education
& biologics direct sales in upper and
market force in the U.S. lower extremities
portfolio

THE

ONLY
PLAYER WITH A SINGULAR FOCUS
ON
EXTREMITIES-BIOLOGICS
5
2017 Strategic Priorities for Growth

Revenue Key Priorities Cash

1. Selectively expand US sales force, 1. Complete integration and realize cost

synergies
~115 new direct, quota-carrying reps
Vision 2. Improve inventory, instruments and
2. PerFORM Reversed Glenoid launch
and continue SIMPLICITI rollout Your First Choice in DSO efficiency
Extremities & Biologics 3. Leverage SG&A
3. Continue AUGMENT rollout

Key Financial Objectives

Mid-teens global Adj. Gross Margins in Expand EBITDA
revenue growth, high 70s% range margins to ~20% by
excluding dis-synergies 2018-2019
Contents are Confidential Wright 6
Wright Extremities: In a High-Growth
Market, Were at ~2X Market Growth Rate
Extend leadership position Accelerate foot & ankle Continued AUGMENT launch
in shoulder with new product growth through market contribution; Leverage
launches and increase sales expansion and sales opportunities for selling biologics
force productivity force optimization across expanded upper and
lower extremities portfolio

UPPER LOWER
BIOLOGICS
EXTREMITIES EXTREMITIES
MARKET
MARKET MARKET

8 9% 8 10% 5 6%
CAGR CAGR CAGR

$2.7B $3.7B $1.7B $2.8B $1.1B $1.4B

2014 2018 2014 2018 2014 2018

Available Market ~$8B

Multiple continued growth opportunities

7
 U.S. Sales Force Expansion Ahead of Schedule:
Reaccelerating our core foot and ankle business

+50 internal
promotions
January
Today
2017
+50 new hires

Lower Extremity Reps

Lower Extremity Reps

MARCH APRIL MAY JUNE JULY ONWARD

Build relationships and
2017 Hiring & promotions Onboarding & training ramp-up new business 8
Strong new
product pipeline
Upper Extremities
to drive growth SIMPLICITI Shoulder System (in rollout)
PerFORM Reversed Glenoid (launched March 2017)
opportunities BluePrint 3D Planning (staged rollout began 1Q17)

Lower Extremities
INFINITY Total Ankle System (in rollout)
SALVATION Limb Salvage System (in rollout)
SALVATION Limb Salvage Line Extensions (anticipated 2H17)
INVISION Revision Ankle System (launched July 2017)
ORTHOLOC 3Di Ankle Fracture LP System (launched July 2017)

Biologics
AUGMENT (in rollout)
AUGMENT Injectable (pursuing PMA-Supplement
with Panel Track)

2016 2017 2018

9
SIMPLICITI Shoulder:
a highlight of our upper extremities product portfolio

99% OF THE PEOPLE WHO HAVE

True Bone Preservation
Canal-sparing design provides
maximal bone preservation and
early intervention options
A SHOULDER REPLACEMENT FOR
ARTHRITIS GET PAIN RELIEF AND SAY
THEY WISH THEY HAD DONE IT SOONER.
Farmer KW, Hammond JW, Queale WS, Keyurapan E, McFarland EG. Shoulder arthroplasty versus
hip and knee arthroplasties: a comparison of outcomes. Clin Orthop Rel Res 2007;455:183-9.

Simplified Anatomic
Alignment
Fewer variables while increasing
accuracy and reproducibility

Opens new market

category
Expands patient pool surgeons
willing to treat

MARKET OPPORTUNITY (U.S.):

$200M-$250M 10
PERFORM Reversed Glenoid:
designed to address all glenoid bone loss

Fixation
Long-term stability with ADAPTIS
Integrated Porous Metal

Augmentation
Specifically shaped for treating
challenging glenoid anatomy

Orientation
Circular design and
independent central screw
allows for an infinitely
adjustable construct

ADDRESSES LARGEST SEGMENT WITHIN

SHOULDER REPLACEMENT
11
Product Pipeline: Upper Extremities

Launched: JUN 2016 PerFORM+ Glenoid

First anatomically shaped Glenoid for treating
patients with difficult glenoid anatomy

Launched: MAR 2017 PerFORM Reversed Glenoid

Anatomically shaped Reversed Glenoid with porous metal
fixation for treating patients with difficult glenoid anatomy

Staged launch
underway: 1Q 2017
BLUEPRINT 3D Planning Software + PSI
Surgeon controlled, patient-specific instrumentation,
allows for accurate positioning of glenoid implant,
visualized bone preservation
US IDE clinical trial
underway PyroCarbon Humeral Head Clinical Study
Proprietary pyrocarbon material closely matches characteristics of bone while
providing low friction, wear resistant articulating surface to extend implant life

BluePrint 3D Planning Software is cleared for use with the Aequalis PerFORM and PerFORM+ Glenoids.
12
INBONE, INFINITY & INVISION:
completing the options
Total Ankle Replacement
Continuum of Care
Designed to relieve pain and
preserve motion in arthritic
ankle joint

High growth, underserved

market

Powered by accuracy of
PROPHECY patient
specific guides

INVISION revision ankle

CURRENT MARKET (U.S.): ~$90M

MARKET OPPORTUNITY (U.S.): ~$500M 13
SALVATION Limb Salvage:
promising new lower extremities product portfolio
THERE ARE AN ESTIMATED 51,000 NEW
CHARCOT PATIENTS PER YEAR IN U.S. ITS
A GLOBAL EPIDEMIC WITH RAPID GROWTH.
http://www.diiabetes.org

First comprehensive solution

for Charcot arthropathy and
advanced midfoot reconstruction
Fusion Bolts &
Large, underserved market Beams

High ASP and resistant to Plating

price pressure System

Full rollout in progress

External Fixator

CURRENT MARKET (U.S.):

$60M-$80M 14
 THE FIRST AND ONLY PROVEN ALTERNATIVE TO
AUGMENT AUTOGRAFT IN ANKLE AND HINDFOOT ARTHRODESIS

Proven
Level 1 evidence of safety and effectiveness
as a replacement to autograft in the largest
F&A clinical trial ever conducted

Labeled
Class III combination product specifically proven
in, and labeled for, ankle and hindfoot arthrodesis
via a rigorous PMA regulatory pathway

Unique
The only biologic product specifically engineered,
proven, and approved for ankle and hindfoot fusions
CURRENT LITERATURE SUGGESTS
Safe
Proven safe through multiple clinical trials and OVERALL NONUNION RATES FOR
successful commercial use since 2009 in Canada ANKLE/HINDFOOT FUSIONS
and 2011 in Australia and New Zealand, while ARE ROUGHLY 10-15%.
eliminating the proven risks, morbidities, and costs
Frey C et al, FAI, 1994; Easley ME et al, JBJS (Am), 2000; Papa J, et al, JBJS (Am), 1993
associated with autograft harvest

MARKET OPPORTUNITY (U.S.):

BIOLOGICS ~$300M 15
Product Pipeline: Lower Extremities and
Biologics

Anticipated Launch:
2H 2017 SALVATION Limb Salvage Line Extensions

Launched: JULY 2017 INVISION Revision Ankle System

Launched: JULY 2017 Next Gen ORTHOLOC 3Di Ankle Fracture LP System

Anticipated Launch:
TBD AUGMENT Injectable
PMA-Supplement with Panel Track*
* Panel Track Supplement does not necessarily result in a panel meeting. It affords FDA additional time to review the submission
beyond 180 days. The current average for Panel Track Supplement review and approval is 300+ days.

16
Clear post-merger path to high growth and
profitability
with more levers coming into play
STEP STEP STEP

1 2 3

Sustain revenue Deliver cost Leverage existing

growth/ minimize synergies of ~$40M resources
disruption to $45M

MID TEENS GROWTH adjusted

once integrated ~20% EBITDA margins
by 2018-2019
ADJ. GROSS MARGINS
high 70s% range
17
Sustained revenue growth
with minimal disruption

Complementary Product Portfolios

Upper Extremities
percentage of revenue

81%
Anticipated
7% Revenue
Dis-Synergies:
~$13M in
Lower Extremities 1H2017
percentage of revenue From sales force integration (~$10M)
and incremental intl Salto ankle

69% divestiture (~$3M)

13%
Based on 2015 YTD pro-forma revenue from continuing operations 18
Clear line of sight to deliver post-merger
cost synergies into 2017-2018
Key
Synergy Public company expenses
Areas
Overlapping support functions Anticipated
Overlapping systems
Cost Synergies
by 2018-2019:
Vendor consolidation ~$40M-$45M
Process improvement

COMPLETED OVER 80% OF ~$30M OF COST SYNERGIES

~300 INTEGRATION MILESTONES IN YEAR 1

19
Opportunity for Significant Leverage Going
Forward >50% of operating expense is highly leverageable

Key Drivers Sizing the Opportunity

% of
Return on previous Op Expense
investments
AUGMENT
14% Depreciation
Amortization } Non-
EBITDA
Re-invest
International Expansion
Sales Force
30%
R&D
Sales Force } at rate of
sales
Medical Education
Hubs
Leverage existing infrastructure
24%
Sales Management
Marketing
Medical Education
} Leverage

32%
Distribution
G&A } Significant
Leverage

100% Total Operating Expense 20

2017 annual guidance

Net Sales Adj. EBITDA

from Continuing from Continuing
Operations(1) Operations(1,2)

$755 million to $78.5 million to

$765 million $85.5 million

$
1 Guidance range communicated on 8/2/2017. The fact that we include these projections in this presentation should not be taken to mean that these amounts
continue to be our projections as of any subsequent date.
2 Adj. EBITDA from continuing operations, which is measured by adding back to net income/loss from continuing operations charges for interest, income taxes,
depreciation and amortization expenses, non-cash share-based compensation expense, and non-operating income and expense 21
Advancing toward our goals
2Q 2017 GOALS
Non-GAAP Once Integrated
Results from With Tornier
Continuing Ops.
SALES
GROWTH 6.3%* Mid teens

ADJ.
GROSS 78.8% High 70s% range
MARGIN
ADJ.
EBITDA 11.0% Adj. EBITDA margins
MARGIN approximately 20%
by 2018-2019

* Constant currency sales growth

22
Wright Medical:
Positioned to Outperform

Leader in 3 of the fastest-growing orthopaedic

markets

Multiple growth drivers via new product pipeline

Post-merger business momentum is increasing

On a faster path to profitability,

with a stronger financial profile

23
For additional information,
please contact:

Julie Tracy
Chief Communications Officer
julie.tracy@wright.com
(901) 290-5817

www.wright.com NASDAQ: WMGI

24
 Positioned to Accelerate

Investor Presentation
August 2, 2017